(a) | (b) | (c) | (d) | (e) | (f) | (g) |
---|---|---|---|---|---|---|
Phrase 1 (containing the Arabic numerical variant) | Number of patients with Phrase 1 only | % of patients missed if searching only for Phrase 1 | Number of patients with both Phrase 1 and Phrase 2 | Number of patients with Phrase 2 only | % of patients missed if searching only for Phrase 2 | Phrase 2 (containing the Roman numerical variant) |
citrullinemia type 1 | 2 | 25.0 | 1 | 1 | 50.0 | citrullinemia type I |
type 2 diabetes mellitus | 43,777 | 10.5 | 7919 | 6053 | 75.8b | type II diabetes mellitus |
type 1 neurofibromatosis | 181 | 24.5 | 56 | 77 | 57.6b | type I neurofibromatosis |
Tanner Stage 3 | 7639 | 57.8b | 1373 | 12,367 | 35.7 | Tanner Stage III |
grade 3 anaplastic astrocytoma | 42 | 36.7 | 27 | 40 | 38.5 | grade III anaplastic astrocytoma |
stage 3 chronic kidney disease | 615 | 67.4b | 446 | 2190 | 18.9 | stage III chronic kidney disease |
factor 9 deficiency | 14 | 68.1b | 51 | 139 | 6.9 | factor IX deficiency |
class 3 malocclusion | 135 | 81.2b | 115 | 1079 | 10.2 | class III malocclusion |
phase 1 clinical trial | 320 | 66.5b | 263 | 1158 | 18.4 | phase I clinical trial |
Mallampati score: 4 | 121 | 27.8 | 1 | 47 | 71.6b | Mallampati score: IV |